- Anne Wojcicki, the CEO and founder of Silicon Valley’s most popular genetics testing startup, 23andMe, said this week that she hopes the company expands its current health offering lineup.
- 23andMe, which made headlines recently on the heels of a new $300-million partnership with drug giant GlaxoSmithKline, currently offers health screenings for some of the genes involved in breast cancer, Alzheimer’s, and Parkinson’s.
- On Tuesday, Wojcicki said she hopes to add a new health offering that looks at how you process medications including those for depression.
- Albertsons pharmacies and gene testing startup Color Genomics currently offer that kind of test for $250-$750, but many scientists say it’s not worth the money.
Anne Wojcicki, the CEO and founder of popular Silicon Valley gene testing company 23andMe, doesn’t feel like the company is currently offering what she called a “complete product.”